Showing 4741-4750 of 8095 results for "".
- Tonight: DEF Webinar Series Kicks Off to Explore COVID-19 Impact on PAs, NPshttps://practicaldermatology.com/news/tonight-def-webinar-series-kicks-off-to-explore-covid-19-impact-on-pas-nps/2460331/Dermatology Education Foundation (DEF) tonight launches a new weekly video series that will focus on the impact of the COVID-19 crisis on dermatology NPs and PAs. Noting that this pandemic presents unprecedented personal and professional hardships and challenges to all practices, DEF ur
- BiomX’s BX001 for Acne-Prone Skin Performs Well in Phase 1 Trialhttps://practicaldermatology.com/news/biomxs-bx001-for-acne-prone-skin-performs-well-in-phase-1-1/2460328/BiomX Inc.’s lead candidate BX001 for acne-prone skin met its primary endpoint of safety and tolerability for both doses of BX001 as well as a statistically significant reduction of Cutibacterium acnes (C. acnes) levels for the high dos
- FDA Approves Lilly's Taltz for Treatment Of Pediatric Patients with Psoriasishttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-treatment-of-pediatric-patients-with-psoriasis/2460327/The FDA has approved a supplemental Biologics License Application (sBLA) for Eli Lilly and Company's Taltz (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are c
- AAD Offers Tips for Practicing in the Era of COVID-19https://practicaldermatology.com/news/aad-offers-tips-for-practicing-in-the-era-of-covid-19/2460313/The American Academy of Dermatology released new guidance for dermatologists amid the COVID-19 crisis including an update on teledermatology and reimbursement codes. The guidance includes: March 19th AAD President’s Message:
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”
- Study: Mohs Scars from Facial Skin Cancers Longer than Patients Expecthttps://practicaldermatology.com/news/study-mohs-scars-from-facial-skin-cancers-longer-than-patients-expect/2460301/Scars from Mohs micrographic surgery for facial skin cancers may be longer than patients expect, according to new research published in JAMA Network Open. In this cross-sectional study of 1
- FDA Accepts NDA for Almirall's AK Drug Tirbanibulinhttps://practicaldermatology.com/news/fda-accepts-nda-for-almiralls-ak-drug-tirbanibulin/2460299/The FDA has reviewed and accepted the New Drug Application (NDA) from Almirall, SA for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis (AK). The FDA also communicated that it is not currently planning on holding an advisory committee to discuss the application. <
- Study: DermTech’s Non-Invasive Gene Expression Testing Improves Early Melanoma Detectionhttps://practicaldermatology.com/news/study-dermtechs-non-invasive-gene-expression-testing-improves-early-melanoma-detection/2460297/A large registry study confirms that DermTech Pigmented Lesion Assay can reduce unnecessary biopsies by up to 90 percent, lower healthcare costs, and rule out melanoma. “The DermTech PLA helps clinicians employ precision dermatology and harness genomics technology to detect malign
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per